<SEC-DOCUMENT>0001104659-22-130567.txt : 20221228
<SEC-HEADER>0001104659-22-130567.hdr.sgml : 20221228
<ACCEPTANCE-DATETIME>20221228170041
ACCESSION NUMBER:		0001104659-22-130567
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20221222
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221228
DATE AS OF CHANGE:		20221228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		221495479

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		(215) 921-7600

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2233572d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20221222">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_fold_amicustherapeutics.com_20221222 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20221222_20221222 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001178879 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityCentralIndexKey">0001178879</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="fold-20221222.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-12-22to2022-12-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-22</xbrli:startDate>
        <xbrli:endDate>2022-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>UNITED
STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>WASHINGTON,
D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt"><b></b>&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20221222__20221222_zlk08TKGpeo7"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>CURRENT
REPORT PURSUANT TO</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECTION
13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Date of Report (Date of
earliest event reported):&#160;<b><span id="xdx_90F_edei--DocumentPeriodEndDate_c20221222__20221222_zPMdzrDOtrSf"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 22, 2022</ix:nonNumeric></span></b></p>

<p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="xdx_90B_edei--EntityRegistrantName_c20221222__20221222_zNFxNkDQerWd"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityRegistrantName">AMICUS THERAPEUTICS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">(Exact
Name of Registrant as Specified in  Its Charter)</p>

<p style="font-size: 10pt; text-align: center; text-indent: -2px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center; width: 32%"><b><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20221222__20221222_zLVefwibJCEh"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></b></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_902_edei--EntityFileNumber_c20221222__20221222_zSk3HL1OPLe6" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityFileNumber">001-33497</ix:nonNumeric></span></td>
    <td style="padding: 2px; text-align: left; width: 2%"><b>&#160;</b></td>
    <td style="padding: 2px; text-align: center; width: 32%"><span id="xdx_90A_edei--EntityTaxIdentificationNumber_c20221222__20221222_zzPCI87yN8cg" style="font: 10pt Times New Roman, Times, Serif"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityTaxIdentificationNumber">71-0869350</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(State
                                            or Other Jurisdiction</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>of Incorporation)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(Commission</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>File Number)</b></span></p></td>
    <td style="padding: 2px; text-align: center"><span style="font-style: normal"><b>&#160;</b></span></td>
    <td style="padding: 2px; text-align: center"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>(I.R.S.
                                            Employer</b></span></p>
        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-style: normal"><b>Identification No.)</b></span></p></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; text-indent: 192px; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_901_edei--EntityAddressAddressLine1_c20221222__20221222_zrGeCjB2q566"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>,
<span id="xdx_90F_edei--EntityAddressCityOrTown_c20221222__20221222_zqTAIqrO04jk"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20221222__20221222_zpxfWvMEZy1j"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric></span> <span id="xdx_907_edei--EntityAddressPostalZipCode_c20221222__20221222_zGQNipjSIBL6"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>(Address of Principal
Executive Offices, and Zip Code)</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_909_edei--CityAreaCode_c20221222__20221222_zqVz6nH7sY3d"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:CityAreaCode">215</ix:nonNumeric></span>-<span id="xdx_90B_edei--LocalPhoneNumber_c20221222__20221222_zxsFRUxFTa99"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:LocalPhoneNumber">921-7600</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>Registrant&#8217;s
Telephone Number, Including Area Code</b></p>

<p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed Since
Last Report.)</p>

<p style="font-size: 10pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-left: 0.5in; font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-size: 10pt; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Wingdings"><span id="xdx_906_edei--WrittenCommunications_c20221222__20221222_zbexo7aW4kPa"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20221222__20221222_zlkdwd9fE8B3"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20221222__20221222_zDoMHwRSDU7k"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font-family: Wingdings"><span id="xdx_90B_edei--PreCommencementIssuerTenderOffer_c20221222__20221222_zDvkCOOG2GJl"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant
to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; margin-right: auto; width: 100%; border-collapse: collapse; text-align: left">
<tr style="vertical-align: bottom">
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><span style="font: normal 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 2%"><span style="font-style: normal; font-weight: normal">&#160;</span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-top: 2px; padding-right: 2px; padding-left: 2px; text-align: center; width: 32%"><p style="margin-top: 0; margin-bottom: 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Name
                                            of each exchange on which registered</span></p></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--Security12bTitle_c20221222__20221222_zSve3bnvkDq9"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:Security12bTitle">Common Stock Par Value $0.01</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--TradingSymbol_c20221222__20221222_zpyZ6qwOO8o"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" name="dei:TradingSymbol">FOLD</ix:nonNumeric></span></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&#160;</td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 2px; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--SecurityExchangeName_c20221222__20221222_zYP0wRmtIkJa"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR &#167;240.12b-2). Emerging growth company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20221222__20221222_zQCzjiqKEHDc" style="font-family: Wingdings"><ix:nonNumeric contextRef="From2022-12-22to2022-12-22" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></p>

<p style="font-size: 10pt; text-align: right; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Item 1.01 &#8211; Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&#160;22, 2022, Amicus Therapeutics,&#160;Inc.
(&#8220;Amicus&#8221; or the &#8220;Company&#8221;) entered into a License Agreement with the Trustees of the University of Pennsylvania
(&#8220;Penn&#8221;) (&#8220;License Agreement&#8221;) pursuant to which Amicus and the Wilson Laboratory at Penn will collaborate to
complete certain wind-down activities in connection with that certain Mutual Termination Agreement, dated December&#160;22, 2022, by and
between Amicus and Penn (&#8220;Termination Agreement&#8221;), and to which Amicus obtains a license with respect to the pre-clinical
research and development of next generation parvovirus gene therapy products for the treatment of Pompe disease and Fabry disease (collectively,
the &#8220;Indications&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As under that certain Amended and Restated Research,
Collaboration and License Agreement with Penn, dated May&#160;28, 2019, as amended (&#8220;Collaboration Agreement&#8221;), under the
License Agreement, Penn granted the Company exclusive, worldwide licenses (with the right to sublicense) under certain patent rights arising
out of the research programs under the Collaboration Agreement and continuing research activities or covering an Amicus-selected parvovirus
gene therapy product developed at Penn and non-exclusive, worldwide licenses (with the right to sublicense) under certain patent rights
pertaining to manufacturing, background patent rights and know-how, in each case, to make, have made, use, sell, offer for sale and import
licensed products for the Indications.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the License Agreement, Penn also granted
the Company an exclusive, worldwide license (with the right to sublicense), for a defined time period, under certain patent rights and
non-exclusive, worldwide license (with the right to sublicense) under certain know-how, in each case, for a multi-year exclusivity period,
to make, have made, use, sell, offer for sale and import certain designated products that incorporate technology pertaining to reduction
of AAV toxicity developed in the laboratories of James M. Wilson, M.D., Ph.D.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All wind-down activities will be overseen by Dr.&#160;Wilson
and will be conducted by the Wilson Laboratory at Penn in accordance with a mutually-agreed research plan and for a specified period of
time and funded by the payments made under the Termination Agreement. As under the Collaboration Agreement, the Company will be responsible
for clinical development and commercialization of the licensed products for the Indications and is obligated to make certain milestone
and royalty payments with respect to licensed products for each Indication.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the License Agreement, and in connection
with the Company&#8217;s funding of the discovery research program under the Termination Agreement, the Company is eligible to receive
a low double-digit percentage share of revenue Penn receives from third-party licensees of certain patent rights generated in the discovery
research program.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the License Agreement
does not purport to be complete and is subject to, and qualified in its entirety by, the full text of such agreement. The Company intends
to seek confidential treatment for certain portions of the License Agreement and expects to file a copy of the License Agreement as an
exhibit to the Company&#8217;s Annual Report on Form&#160;10-K for the year ending December&#160;31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Item 1.02 &#8211; Termination of a Material
Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&#160;22, 2022, Amicus entered into
the Termination Agreement pursuant to which Amicus and Penn terminated the Collaboration Agreement and the Process and Development Agreement,
dated March&#160;26, 2020, by and between Amicus and Penn, as amended. Under the Collaboration Agreement, Amicus and the Wilson Laboratory
at Penn collaborated with respect to the pre-clinical research and development of next generation parvovirus gene therapy products for
the treatment of Pompe disease, Fabry disease, CDKL5 deficiency (&#8220;CDKL5&#8221;), Niemann Pick Type C, Mucopolysaccharidosis Type
IIIA (&#8220;MPS IIIA&#8221;), Mucopolysaccharidosis Type IIIB, Duchenne muscular dystrophy (&#8220;DMD&#8221;) and Angelman Syndrome
(&#8220;Angelman&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Termination Agreement, Penn granted to
Amicus certain non-exclusive rights to results pertaining to DMD and Angelman studies and Amicus granted to Penn certain option rights
with respect to technology pertaining to each of CDKL5 and MPS IIIA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, and in connection with Penn&#8217;s
delivery of certain deliverables arising from the Collaboration Agreement and remaining discovery support payment obligations under the
Collaboration Agreement, Amicus paid to Penn an unpaid portion of such discovery support payments amounting to $20 million. Further, in
connection with winding down the research program activities as originally contemplated under the Collaboration Agreement, Amicus paid
to Penn certain research support amounts and related wind-down costs in the low single digit million payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Termination Agreement
does not purport to be complete and is subject to, and qualified in its entirety by, the full text of such agreement. The Company intends
to seek confidential treatment for certain portions of the Termination Agreement and expects to file a copy of the Agreement as an exhibit
to the Company&#8217;s Annual Report on Form&#160;10-K for the year ending December&#160;31, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><b>Item 5.02 &#8211; Departure
of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&#160;26, 2022, members of the board
of directors of the Company (the &#8220;Board&#8221;) entered into an updated director and officer indemnification agreement (the &#8220;Indemnification
Agreement&#8221;). The Indemnification Agreement replaces and supersedes previous indemnification agreements between the Company and each
executing director and officer. The Company intends to use the Indemnification Agreement as a form with each of its directors and officers
from and after December&#160;26, 2022. The Indemnification Agreement will, among other things, require the Company to indemnify each executing
director and officer to the fullest extent permitted by Delaware law, including indemnification of certain expenses incurred by the director
or officer in any action or proceeding brought by third-parties or by or in the right of Amicus, arising out of each individual&#8217;s
services as an officer or director, provided he or she has acted in good faith. <span style="background-color: white">The rights contained
in the Indemnification Agreement are in addition to any other rights an indemnitee may have under the Company&#8217;s organizational documents
or applicable law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Indemnification
Agreement is not complete and is subject to and qualified in its entirety by reference to the form of Indemnification Agreement, a copy
of which is attached hereto as Exhibit&#160;10.1 and the terms of which are incorporated by reference herein. The information set forth
under this Item 5.02 of this Current Report on Form&#160;8-K is incorporated into Item 1.01 by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><b>(d)&#160;Exhibits:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 22%; text-align: center"><b>Exhibit&#160;No.</b></td>
    <td style="width: 78%; text-align: center"><b>Description</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-top: black 1pt solid; text-align: center"><a href="tm2233572d1_ex10-1.htm">10.1</a></td>
    <td style="border-top: black 1pt solid"><a href="tm2233572d1_ex10-1.htm">Form&#160;of Director and Officer Indemnification Agreement</a></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">104</td>
    <td>Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 238.8pt"><b><span style="text-decoration: underline">Signature Page</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.25in">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">AMICUS THERAPEUTICS,&#160;INC.</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">Date: December&#160;28, 2022</td>
    <td style="width: 3%">By:</td>
    <td style="border-bottom: Black 1pt solid; width: 47%">/s/ Ellen S. Rosenberg</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">Name: Ellen S. Rosenberg</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2">Title: Chief Legal Officer and Corporate Secretary</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk0KovbRokWsIkXE19iuEmyzZRP/juQtjS3isrAsM9+MEAOR0dLUyHCcFznssWlr7REKPCOjLTE40tU6gXALvBjnWVvfvT8wpcBgYMZDeSqD0FnvxmGVgJyO5GSkZiBniVKw24joq6dkz6ZC642uQdsKdkwtG/SaX33CXj/JUvPqqg7IzpBNQA1lL78hliqGLd31g/jqIM9TEQ26iUTGdGu/NTfnqYFFjU3ocj363+gDPyxJhA== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2233572d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>INDEMNITY AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS INDEMNITY AGREEMENT
</B>(this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made as of [&#9679;], by and between Amicus Therapeutics,&nbsp;Inc., a Delaware corporation
(the &ldquo;<B><I>Corporation</I></B>&rdquo;), and [&#9679;] (&ldquo;<B><I>Indemnitee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS,</B> highly competent
persons have become more reluctant to serve publicly held corporations as directors, officers or in other capacities unless they are
provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against
them arising out of their service to and activities on behalf of such corporations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS,</B> the uncertainties
relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, the Board
has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Corporation&rsquo;s
stockholders and that the Corporation should act to assure such persons that there will be increased certainty of such protection in
the future;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>the Board
of Directors of the Corporation (the &ldquo;<B><I>Board</I></B>&rdquo;) has determined that, in order to attract and retain qualified
individuals, the Corporation will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons
serving the Corporation and its subsidiaries from certain liabilities. The certificate of incorporation of the Corporation limits the
liability of the members of the Board to the fullest extent permitted by the Delaware General Corporation Law, and the bylaws of the
Corporation (the &ldquo;<B><I>Bylaws</I></B>&rdquo;) provide that the Corporation will indemnify them to the fullest extent permitted
by such law. The Bylaws provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that
contracts may be entered into between the Corporation and members of the Board, officers and other persons with respect to indemnification
and advancement rights;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>it is reasonable,
prudent and necessary for the Corporation contractually to obligate itself to indemnify and to advance expenses on behalf of, such persons
to the fullest extent permitted by applicable law so that they will serve or continue to serve the Corporation free from undue concern
that they will not be so protected against liabilities; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS, </B>this Agreement
is a supplement to and in furtherance of the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute
therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE, </B>in
consideration of the premises and the covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Corporation
and Indemnitee do hereby covenant and agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>SERVICES TO THE CORPORATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In consideration of the Corporation&rsquo;s
covenants and obligations hereunder,&nbsp;Indemnitee will serve or continue to serve as an officer, director, advisor, key employee or
in any other capacity of the Corporation, as applicable, for so long as Indemnitee is duly elected, appointed or retained or until Indemnitee
tenders his or her resignation or until Indemnitee is removed. The foregoing notwithstanding, this Agreement shall continue in full force
and effect after Indemnitee has ceased to serve as a director, officer, advisor, key employee or in any other capacity of the Corporation,
as provided in Section&nbsp;17. This Agreement, however, shall not impose any obligation on Indemnitee or the Corporation to continue
Indemnitee&rsquo;s service to the Corporation beyond any period otherwise required by law or by other agreements or commitments of the
parties, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>DEFINITIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">References to &ldquo;<B><I>agent</I></B>&rdquo;
                                            shall mean any person who is or was a director, officer or employee of the Corporation or
                                            a subsidiary of the Corporation or other person authorized by the Corporation to act for
                                            the Corporation, to include such person serving in such capacity as a director, officer,
                                            employee, advisor, fiduciary or other official of another corporation, partnership, limited
                                            liability company, joint venture, trust or other enterprise at the request of, for the convenience
                                            of, or to represent the interests of the Corporation or a subsidiary of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The terms &ldquo;<B><I>Beneficial Owner</I></B>&rdquo;
                                            and &ldquo;<B><I>Beneficial Ownership</I></B>&rdquo; shall have the meanings set forth in
                                            Rule&nbsp;13d-3 promulgated under the Exchange Act as in effect on the date hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">A &ldquo;<B><I>Change in Control</I></B>&rdquo;
                                            shall be deemed to occur upon the earliest to occur after the date of this Agreement of any
                                            of the following events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><U>Acquisition of Shares by Third Party</U>.
                                            Any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the
                                            Corporation representing fifteen percent (15%) or more of the combined voting power of the
                                            Corporation&rsquo;s then outstanding securities entitled to vote generally in the election
                                            of directors, unless (1)&nbsp;the change in the relative Beneficial Ownership of the Corporation&rsquo;s
                                            securities by any Person results solely from a reduction in the aggregate number of outstanding
                                            shares of securities entitled to vote generally in the election of directors, or (2)&nbsp;such
                                            acquisition was approved in advance by the Continuing Directors and such acquisition would
                                            not constitute a Change in Control under part&nbsp;(iii)&nbsp;of this definition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><U>Change in Board of Directors</U>. Individuals
                                            who, as of the date hereof, constitute the Board, and any new director whose election by
                                            the Board or nomination for election by the Corporation&rsquo;s stockholders was approved
                                            by a vote of at least two thirds of the directors then still in office who were directors
                                            on the date hereof or whose election or nomination for election was previously so approved
                                            (collectively, the &ldquo;<B><I>Continuing Directors</I></B>&rdquo;), cease for any reason
                                            to constitute at least a majority of the members of the Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><U>Corporate Transactions</U>. The effective
                                            date of a merger, share exchange, asset acquisition, share purchase, reorganization or similar
                                            business combination, involving the Corporation and one or more businesses (a &ldquo;<B><I>Business
                                            Combination</I></B>&rdquo;), in each case, unless, following such Business Combination: (1)&nbsp;all
                                            or substantially all of the individuals and entities who were the Beneficial Owners of securities
                                            entitled to vote generally in the election of directors immediately prior to such Business
                                            Combination beneficially own, directly or indirectly, more than 51% of the combined voting
                                            power of the then outstanding securities of the Corporation entitled to vote generally in
                                            the election of directors resulting from such Business Combination (including, without limitation,
                                            a corporation which as a result of such transaction owns the Corporation or all or substantially
                                            all of the Corporation&rsquo;s assets either directly or through one or more Subsidiaries)
                                            in substantially the same proportions as their ownership immediately prior to such Business
                                            Combination, of the securities entitled to vote generally in the election of directors; (2)&nbsp;no
                                            Person (excluding any corporation resulting from such Business Combination) is the Beneficial
                                            Owner, directly or indirectly, of 15% or more of the combined voting power of the then outstanding
                                            securities entitled to vote generally in the election of directors of the surviving corporation
                                            except to the extent that such ownership existed prior to the Business Combination; and (3)&nbsp;at
                                            least a majority of the board of directors of the corporation resulting from such Business
                                            Combination were Continuing Directors at the time of the execution of the initial agreement,
                                            or of the action of the Board, providing for such Business Combination;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><U>Liquidation</U>. The approval by the
                                            stockholders of the Corporation of a complete liquidation of the Corporation or an agreement
                                            or series of agreements for the sale or disposition by the Corporation of all or substantially
                                            all of the Corporation&rsquo;s assets, other than factoring the Corporation&rsquo;s current
                                            receivables or escrows due (or, if such approval is not required, the decision by the Board
                                            to proceed with such a liquidation, sale, or disposition in one transaction or a series of
                                            related transactions); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify"><U>Other Events</U>. There occurs any other
                                            event of a nature that would be required to be reported in response to Item 6(e)&nbsp;of
                                            Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule
                                            or form) promulgated under the Exchange Act, whether or not the Corporation is then subject
                                            to such reporting requirement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Corporate Status</I></B>&rdquo;
                                            describes the status of a person who is or was a director, officer, trustee, general partner,
                                            manager, managing member, fiduciary, employee or agent of the Corporation or of any other
                                            Enterprise which such person is or was serving at the request of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Delaware Court</I></B>&rdquo;
                                            shall mean the Court of Chancery of the State of Delaware.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Disinterested Director</I></B>&rdquo;
                                            shall mean a director of the Corporation who is not and was not a party to the Proceeding
                                            in respect of which indemnification is sought by Indemnitee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Enterprise</I></B>&rdquo;
                                            shall mean the Corporation and any other corporation, constituent corporation (including
                                            any constituent of a constituent) absorbed in a consolidation or merger to which the Corporation
                                            (or any of its wholly owned subsidiaries) is a party, limited liability company, partnership,
                                            joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or
                                            was serving at the request of the Corporation as a director, officer, trustee, general partner,
                                            managing member, manager, fiduciary, employee or agent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Exchange Act</I></B>&rdquo;
                                            shall mean the Securities Exchange Act of 1934, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Expenses</I></B>&rdquo; shall
                                            include all direct and indirect costs, fees and expenses of any type or nature whatsoever,
                                            including, without limitation, all reasonable attorneys&rsquo; fees and costs, retainers,
                                            court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private
                                            investigators and professional advisors, duplicating costs, printing and binding costs, telephone
                                            charges, postage, delivery service fees, fax transmission charges, secretarial services and
                                            all other disbursements, obligations or expenses in connection with prosecuting, defending,
                                            preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement
                                            or appeal of, or otherwise participating in, a Proceeding, including reasonable compensation
                                            for time spent by the Indemnitee for which he or she is not otherwise compensated by the
                                            Corporation or any third party. Expenses also shall include Expenses incurred in connection
                                            with any appeal resulting from any Proceeding, including, without limitation, the principal,
                                            premium, security for, and other costs relating to any cost bond, supersedeas bond, or other
                                            appeal bond or its equivalent. Expenses, however, shall not include amounts paid in settlement
                                            by Indemnitee or the amount of judgments or fines against Indemnitee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD STYLE="text-align: justify">References to &ldquo;<B><I>fines</I></B>&rdquo;
                                            shall include any excise tax assessed on Indemnitee with respect to any employee benefit
                                            plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD STYLE="text-align: justify">References to &ldquo;<B><I>serving at
                                            the request of the Corporation</I></B>&rdquo; shall include any service as a director, officer,
                                            employee, agent or fiduciary of the Corporation which imposes duties on, or involves services
                                            by, such director, officer, employee, agent or fiduciary with respect to an employee benefit
                                            plan, its participants or beneficiaries; and if Indemnitee acted in good faith and in a manner
                                            Indemnitee reasonably believed to be in the best interests of the participants and beneficiaries
                                            of an employee benefit plan,&nbsp;Indemnitee shall be deemed to have acted in a manner &ldquo;<B><I>not
                                            opposed to the best interests of the Corporation</I></B>&rdquo; as referred to in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD STYLE="text-align: justify">&ldquo;<B><I>Independent Counsel</I></B>&rdquo;
                                            shall mean a law firm or a member of a law firm with significant experience in matters of
                                            corporate law and that neither presently is, nor in the past five years has been, retained
                                            to represent: (i)&nbsp;the Corporation or Indemnitee in any matter material to either such
                                            party (other than with respect to matters concerning Indemnitee under this Agreement, or
                                            of other indemnitees under similar indemnification agreements); or (ii)&nbsp;any other party
                                            to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
                                            foregoing, the term &ldquo;<B><I>Independent Counsel</I></B>&rdquo; shall not include any
                                            person who, under the applicable standards of professional conduct then prevailing, would
                                            have a conflict of interest in representing either the Corporation or Indemnitee in an action
                                            to determine Indemnitee&rsquo;s rights under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD STYLE="text-align: justify">The term &ldquo;<B><I>Person</I></B>&rdquo;
                                            shall have the meaning as set forth in Sections 13(d)&nbsp;and 14(d)&nbsp;of the Exchange
                                            Act as in effect on the date hereof; <I>provided, however</I>, that &ldquo;<B><I>Person</I></B>&rdquo;
                                            shall exclude: (i)&nbsp;the Corporation; (ii)&nbsp;any Subsidiaries of the Corporation; (iii)&nbsp;any
                                            employment benefit plan of the Corporation or of a Subsidiary of the Corporation or of any
                                            corporation owned, directly or indirectly, by the stockholders of the Corporation in substantially
                                            the same proportions as their ownership of shares of the Corporation; and (iv)&nbsp;any trustee
                                            or other fiduciary holding securities under an employee benefit plan of the Corporation or
                                            of a Subsidiary of the Corporation or of a corporation owned directly or indirectly by the
                                            stockholders of the Corporation in substantially the same proportions as their ownership
                                            of shares of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD STYLE="text-align: justify">The term &ldquo;<B><I>Proceeding</I></B>&rdquo;
                                            shall include any threatened, pending or completed action, suit, arbitration, mediation,
                                            alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or
                                            any other actual, threatened or completed proceeding, whether brought in the right of the
                                            Corporation or otherwise and whether of a civil (including intentional or unintentional tort
                                            claims), criminal, administrative or investigative or related nature, in which Indemnitee
                                            was, is, will or might be involved as a party or otherwise by reason of the fact that Indemnitee
                                            is or was a director or officer of the Corporation, by reason of any action (or failure to
                                            act) taken by him or her or of any action (or failure to act) on his or her part while acting
                                            as a director or officer of the Corporation, or by reason of the fact that he or she is or
                                            was serving at the request of the Corporation as a director, officer, trustee, general partner,
                                            managing member, manager, fiduciary, employee or agent of any other Enterprise, in each case
                                            whether or not serving in such capacity at the time any liability or expense is incurred
                                            for which indemnification or advancement of expenses can be provided under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD STYLE="text-align: justify">The term &ldquo;<B><I>Subsidiary</I></B>,&rdquo;
                                            with respect to any Person, shall mean any corporation, limited liability company, partnership,
                                            joint venture, trust or other entity of which a majority of the voting power of the voting
                                            equity securities or equity interest is owned, directly or indirectly, by that Person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD STYLE="text-align: justify">The phrase &ldquo;to the fullest extent
                                            permitted by applicable law&rdquo; shall include, but not be limited to: (a)&nbsp;to the
                                            fullest extent authorized or permitted by the provision of applicable Delaware law that authorizes
                                            or contemplates additional indemnification by agreement, or the corresponding provision of
                                            any amendment to or replacement of applicable Delaware law, and (b)&nbsp;to the fullest extent
                                            authorized or permitted by any amendments to or replacements of applicable Delaware law adopted
                                            after the date of this Agreement that increase the extent to which a corporation may indemnify
                                            its officers and directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B>INDEMNITY IN THIRD-PARTY PROCEEDINGS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Corporation shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;3 if Indemnitee
was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding, other than
a Proceeding by or in the right of the Corporation to procure a judgment in its favor by reason of Indemnitee&rsquo;s Corporate Status.
Pursuant to this Section&nbsp;3,&nbsp;Indemnitee shall be indemnified, held harmless and exonerated against all Expenses, judgments,
liabilities, fines, penalties and amounts paid in settlement (including all interest, assessments and other charges paid or payable in
connection with or in respect of such Expenses, judgments, fines, penalties and amounts paid in settlement) actually, and reasonably
incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Corporation and,
in the case of a criminal Proceeding, had no reasonable cause to believe that his or her conduct was unlawful; <I>provided</I> that no
indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged to be liable to
the Corporation unless and only to the extent that the Delaware Court or the court in which such action or suit was brought shall determine
upon application that, despite the adjudication of liability but in view of all the circumstances of the Proceeding,&nbsp;Indemnitee
is fairly and reasonably entitled to indemnity for such expenses which the Delaware Court or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B>INDEMNITY IN PROCEEDINGS BY OR IN
                                            THE RIGHT OF THE CORPORATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the fullest extent permitted
by applicable law, the Corporation shall indemnify Indemnitee in accordance with the provisions of this Section&nbsp;4 if Indemnitee
was, is, or is threatened to be made, a party to or a participant (as a witness, deponent or otherwise) in any Proceeding by or in the
right of the Corporation to procure a judgment in its favor by reason of Indemnitee&rsquo;s Corporate Status. Pursuant to this Section&nbsp;4,&nbsp;Indemnitee
shall be indemnified, held harmless and exonerated against all Expenses actually and reasonably incurred by him or her or on his or her
behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in or not opposed to the best interests of the Corporation. No indemnification for Expenses shall be
made under this Section&nbsp;4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a
court of competent jurisdiction to be liable to the Corporation, unless and only to the extent that any court in which the Proceeding
was brought or the Delaware Court shall determine upon application that, despite the adjudication of liability but in view of all the
circumstances of the case,&nbsp;Indemnitee is fairly and reasonably entitled to indemnification, to be held harmless or to exoneration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>5.</B></TD><TD STYLE="text-align: justify"><B>INDEMNIFICATION FOR EXPENSES OF A
                                            PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provisions of this Agreement, but subject to Section&nbsp;27, to the extent that Indemnitee was or is, by reason of Indemnitee&rsquo;s
Corporate Status, a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of
any claim, issue or matter therein, in whole or in part, the Corporation shall, to the fullest extent permitted by applicable law, indemnify
Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful
in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such
Proceeding, the Corporation shall, to the fullest extent permitted by applicable law, indemnify Indemnitee against all Expenses actually
and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter. If
Indemnitee is not wholly successful in such Proceeding, the Corporation also shall, to the fullest extent permitted by applicable law,
indemnify Indemnitee against all Expenses reasonably incurred in connection with a claim, issue or matter related to any claim, issue,
or matter on which Indemnitee was successful. For purposes of this Section&nbsp;5 and without limitation, the termination of any claim,
issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim,
issue or matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>6.</B></TD><TD STYLE="text-align: justify"><B>INDEMNIFICATION FOR EXPENSES OF A
                                            WITNESS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any other
provision of this Agreement, but subject to Section&nbsp;27, to the extent that Indemnitee is, by reason of his or her Corporate Status,
a witness or deponent in any Proceeding to which Indemnitee is not a party or threatened to be made a party, he or she shall, to the
fullest extent permitted by applicable law, be indemnified, held harmless and exonerated against all Expenses actually and reasonably
incurred by him or her or on his or her behalf in connection therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>7.</B></TD><TD STYLE="text-align: justify"><B>ADDITIONAL INDEMNIFICATION RIGHTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any limitation
in Sections&nbsp;3, 4 or 5, but subject to Section&nbsp;27, the Corporation shall, to the fullest extent permitted by applicable law,
indemnify Indemnitee if Indemnitee is a party to or threatened to be made a party to any Proceeding (including a Proceeding by or in
the right of the Corporation to procure a judgment in its favor) against all Expenses, judgments, fines, penalties and amounts paid in
settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses,
judgments, fines, penalties and amounts paid in settlement) actually and reasonably incurred by Indemnitee in connection with the Proceeding.
No indemnification rights shall be available under this Section&nbsp;7 on account of Indemnitee&rsquo;s conduct which constitutes a breach
of Indemnitee&rsquo;s duty of loyalty to the Corporation or its stockholders or is an act or omission not in good faith or which involves
intentional misconduct or a knowing violation of the law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>8.</B></TD><TD STYLE="text-align: justify"><B>CONTRIBUTION IN THE EVENT OF JOINT
                                            LIABILITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">To the fullest extent permissible under
                                            applicable law, if the indemnification rights provided for in this Agreement are unavailable
                                            to Indemnitee in whole or in part for any reason whatsoever, the Corporation, in lieu of
                                            indemnifying Indemnitee, shall pay, in the first instance, the entire amount incurred by
                                            Indemnitee, whether for judgments, liabilities, fines, penalties, amounts paid or to be paid
                                            in settlement and/or for Expenses, in connection with any Proceeding without requiring Indemnitee
                                            to contribute to such payment, and the Corporation hereby waives and relinquishes any right
                                            of contribution it may have at any time against Indemnitee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Corporation shall not enter into any
                                            settlement of any Proceeding in which the Corporation is jointly liable with Indemnitee (or
                                            would be if joined in such Proceeding) unless such settlement provides for a full and final
                                            release of all claims asserted against Indemnitee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Corporation hereby agrees to fully
                                            indemnify Indemnitee from any claims for contribution which may be brought by officers, directors
                                            or employees of the Corporation other than Indemnitee who may be jointly liable with Indemnitee.
                                            Indemnitee shall seek payments or advances from the Corporation only to the extent that such
                                            payments or advances are unavailable from any insurance policy of the Corporation covering
                                            Indemnitee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>9.</B></TD><TD STYLE="text-align: justify"><B>EXCLUSIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding any provision
in this Agreement, but subject to Section&nbsp;27, the Corporation shall not be obligated under this Agreement to make any indemnification
or advance Expenses payment in connection with any claim made against Indemnitee:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">for which payment has actually been received
                                            by or on behalf of Indemnitee under any insurance policy or other indemnity or advancement
                                            provision and which payment has not subsequently been returned, except with respect to any
                                            excess beyond the amount actually received under any insurance policy, contract, agreement,
                                            other indemnity or advancement provision or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">for an accounting of profits made from
                                            the purchase and sale (or sale and purchase) by Indemnitee of securities of the Corporation
                                            within the meaning of Section&nbsp;16(b)&nbsp;of the Exchange Act (or any successor rule)
                                            or similar provisions of state statutory law or common law; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">except as otherwise provided in Sections&nbsp;14(f)&nbsp;and
                                            (g)&nbsp;hereof, prior to a Change in Control, in connection with any Proceeding (or any
                                            part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of
                                            any Proceeding) initiated by Indemnitee against the Corporation or its directors, officers,
                                            employees or other indemnitees, unless (i)&nbsp;the Board authorized the Proceeding (or any
                                            part of any Proceeding) prior to its initiation or (ii)&nbsp;the Corporation provides the
                                            indemnification payment, in its sole discretion, pursuant to the powers vested in the Corporation
                                            under applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>10.</B></TD><TD STYLE="text-align: justify"><B>ADVANCES OF EXPENSES; DEFENSE OF
                                            CLAIM</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding any provision of this
                                            Agreement to the contrary, but subject to Section&nbsp;27, and to the fullest extent not
                                            prohibited by applicable law, the Corporation shall pay the Expenses incurred by Indemnitee
                                            (or reasonably expected by Indemnitee to be incurred by Indemnitee within three months) in
                                            connection with any Proceeding within ten (10)&nbsp;days after the receipt by the Corporation
                                            of a statement or statements requesting such advances from time to time, prior to the final
                                            disposition of any Proceeding. Advances shall, to the fullest extent permitted by law, be
                                            unsecured and interest free. Advances shall, to the fullest extent permitted by law, be made
                                            without regard to Indemnitee&rsquo;s ability to repay the Expenses and without regard to
                                            Indemnitee&rsquo;s ultimate entitlement to be indemnified, held harmless or exonerated under
                                            the other provisions of this Agreement. Advances shall include any and all reasonable Expenses
                                            incurred pursuing a Proceeding to enforce this right of advancement, including Expenses incurred
                                            preparing and forwarding statements to the Corporation to support the advances claimed. To
                                            the fullest extent required by applicable law, such payments of Expenses in advance of the
                                            final disposition of the Proceeding shall be made only upon the Corporation&rsquo;s receipt
                                            of an undertaking, by or on behalf of Indemnitee, to repay the advanced amounts only if,
                                            and to the extent that it is ultimately determined that Indemnitee is not entitled to be
                                            indemnified by the Corporation under the provisions of this Agreement, the Bylaws, applicable
                                            law or otherwise. If it shall be determined by a final judgment or other final adjudication
                                            that Indemnitee was not so entitled to indemnification, any advancement shall be returned
                                            to the Corporation (without interest) by the Indemnitee. This Section&nbsp;10(a)&nbsp;shall
                                            not apply to any claim made by Indemnitee for which an indemnification payment is excluded
                                            pursuant to Section&nbsp;9, but shall apply to any Proceeding referenced in Section&nbsp;9(b)&nbsp;prior
                                            to a final determination that Indemnitee is liable therefor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Corporation will be entitled to participate
                                            in the Proceeding at its own expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Corporation shall not settle any action,
                                            claim or Proceeding (in whole or in part) which would impose any Expense, judgment, fine,
                                            penalty or limitation on Indemnitee without Indemnitee&rsquo;s prior written consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>11.</B></TD><TD STYLE="text-align: justify"><B>PROCEDURE FOR NOTIFICATION AND APPLICATION
                                            FOR INDEMNIFICATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Indemnitee shall, as a condition precedent
                                            to the right to be indemnified under this Agreement, notify the Corporation in writing as
                                            soon as practicable of any claim made against Indemnitee for which indemnification rights
                                            or advancement of Expenses, will or could be sought under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Such notice of a claim shall include a
                                            request to indemnify Indemnitee in accordance with this Agreement, and shall be delivered
                                            to the Corporation in accordance with Section&nbsp;21 of this Agreement. In addition,&nbsp;Indemnitee
                                            shall give the Corporation such information and cooperation as it may reasonably require
                                            and as shall be within Indemnitee's power. Following the Corporation&rsquo;s receipt of such
                                            request for indemnification,&nbsp;Indemnitee&rsquo;s entitlement to indemnification shall
                                            be determined according to Section&nbsp;12(a)&nbsp;of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>12.</B></TD><TD STYLE="text-align: justify"><B>PROCEDURE UPON APPLICATION FOR INDEMNIFICATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">A determination, if required by applicable
                                            law, with respect to Indemnitee&rsquo;s entitlement to indemnification shall be made in the
                                            specific case by one of the following methods, which shall be at the election of Indemnitee:
                                            (i)&nbsp;by a majority vote of the Disinterested Directors, even though less than a quorum
                                            of the Board, (ii)&nbsp;by a committee of such directors designated by majority vote of such
                                            directors, (iii)&nbsp;if there are no Disinterested Directors or if such directors so direct,
                                            by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered
                                            to Indemnitee, or (iv)&nbsp;by vote of the stockholders by ordinary resolution. The Corporation
                                            promptly will advise Indemnitee in writing with respect to any determination that Indemnitee
                                            is or is not entitled to indemnification, including a description of any reason or basis
                                            for which indemnification has been denied. If it is so determined that Indemnitee is entitled
                                            to indemnification, payment to Indemnitee shall be made within ten (10)&nbsp;days after such
                                            determination. Indemnitee shall reasonably cooperate with the person, persons or entity making
                                            such determination with respect to Indemnitee&rsquo;s entitlement to indemnification, including
                                            providing to such person, persons or entity upon reasonable advance request any documentation
                                            or information which is not privileged or otherwise protected from disclosure and which is
                                            reasonably available to Indemnitee and reasonably necessary to such determination. Any costs
                                            or Expenses (including reasonable attorneys&rsquo; fees and disbursements) incurred by Indemnitee
                                            in so cooperating with the person, persons or entity making such determination shall be borne
                                            by the Corporation (irrespective of the determination as to Indemnitee&rsquo;s entitlement
                                            to indemnification) and the Corporation hereby agrees to indemnify therefrom.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event the determination of entitlement
                                            to indemnification is to be made by Independent Counsel pursuant to Section&nbsp;12(a)&nbsp;hereof,
                                            the Independent Counsel shall be selected as provided in this Section&nbsp;12(b). The Independent
                                            Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection
                                            be made by the Board), and Indemnitee shall give written notice to the Corporation advising
                                            it of the identity of the Independent Counsel so selected and certifying that the Independent
                                            Counsel so selected meets the requirements of &ldquo;Independent Counsel&rdquo; as defined
                                            in Section&nbsp;2 of this Agreement. If the Independent Counsel is selected by the Board,
                                            the Corporation shall give written notice to Indemnitee advising him or her of the identity
                                            of the Independent Counsel so selected and certifying that the Independent Counsel so selected
                                            meets the requirements of &ldquo;Independent Counsel&rdquo; as defined in Section&nbsp;2
                                            of this Agreement. In either event,&nbsp;Indemnitee or the Corporation, as the case may be,
                                            may, within ten (10)&nbsp;days after such written notice of selection shall have been received,
                                            deliver to the Corporation or to Indemnitee, as the case may be, a written objection to such
                                            selection; <I>provided, however</I>, that such objection may be asserted only on the ground
                                            that the Independent Counsel so selected does not meet the requirements of &ldquo;Independent
                                            Counsel&rdquo; as defined in Section&nbsp;2 of this Agreement, and the objection shall set
                                            forth with particularity the factual basis of such assertion. Absent a proper and timely
                                            objection, the person so selected shall act as Independent Counsel. If such written objection
                                            is so made and substantiated, the Independent Counsel so selected may not serve as Independent
                                            Counsel unless and until such objection is withdrawn or a court of competent jurisdiction
                                            has determined that such objection is without merit. If, within twenty (20) days after submission
                                            by Indemnitee of a written request for indemnification pursuant to Section&nbsp;11(b)&nbsp;hereof,
                                            no Independent Counsel shall have been selected and not objected to, either the Corporation
                                            or Indemnitee may petition the Delaware Court for resolution of any objection which shall
                                            have been made by the Corporation or Indemnitee to the other&rsquo;s selection of Independent
                                            Counsel and/or for the appointment as Independent Counsel of a person selected by the Delaware
                                            Court, and the person with respect to whom all objections are so resolved or the person so
                                            appointed shall act as Independent Counsel under Section&nbsp;12(a)&nbsp;hereof. Upon the
                                            due commencement of any judicial proceeding or arbitration pursuant to Section&nbsp;14(a)&nbsp;of
                                            this Agreement,&nbsp;Independent Counsel shall be discharged and relieved of any further
                                            responsibility in such capacity (subject to the applicable standards of professional conduct
                                            then prevailing).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Corporation agrees to pay the reasonable
                                            fees and expenses of Independent Counsel and to fully indemnify such Independent Counsel
                                            against any and all Expenses, claims, liabilities and damages arising out of or relating
                                            to this Agreement or its engagement pursuant hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>13.</B></TD><TD STYLE="text-align: justify"><B>PRESUMPTIONS AND EFFECT OF CERTAIN
                                            PROCEEDINGS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In making a determination with respect
                                            to entitlement to indemnification hereunder, the person, persons or entity making such determination
                                            shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee
                                            has submitted a request for indemnification in accordance with Section&nbsp;11(b)&nbsp;of
                                            this Agreement, and the Corporation shall have the burden of proof to overcome that presumption
                                            in connection with the making by any person, persons or entity of any determination contrary
                                            to that presumption. Neither the failure of the Corporation (including by the Disinterested
                                            Directors or Independent Counsel) to have made a determination prior to the commencement
                                            of any action pursuant to this Agreement that indemnification is proper in the circumstances
                                            because Indemnitee has met the applicable standard of conduct, nor an actual determination
                                            by the Corporation (including by the Disinterested Directors or Independent Counsel) that
                                            Indemnitee has not met such applicable standard of conduct, shall be a defense to the action
                                            or create a presumption that Indemnitee has not met the applicable standard of conduct.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If the person, persons or entity empowered
                                            or selected under Section&nbsp;12 of this Agreement to determine whether Indemnitee is entitled
                                            to indemnification shall not have made a determination within thirty (30) days after receipt
                                            by the Corporation of the request therefor, the requisite determination of entitlement to
                                            indemnification shall, to the fullest extent permitted by law, be deemed to have been made
                                            and Indemnitee shall be entitled to such indemnification, absent (i)&nbsp;a misstatement
                                            by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s
                                            statement not materially misleading, in connection with the request for indemnification,
                                            or (ii)&nbsp;a final judicial determination that any or all such indemnification is expressly
                                            prohibited under applicable law; <I>provided, however</I>, that such 30-day period may be
                                            extended for a reasonable time, not to exceed an additional fifteen (15) days, if the person,
                                            persons or entity making the determination with respect to entitlement to indemnification
                                            in good faith requires such additional time for the obtaining or evaluating of documentation
                                            and/or information relating thereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The termination of any Proceeding or of
                                            any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon
                                            a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided
                                            in this Agreement) of itself adversely affect the right of Indemnitee to indemnification
                                            or create a presumption that Indemnitee did not act in good faith and in a manner which he
                                            or she reasonably believed to be in or not opposed to the best interests of the Corporation
                                            and, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe
                                            that his or her conduct was unlawful.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">For purposes of any determination of good
                                            faith,&nbsp;Indemnitee shall be deemed to have acted in good faith if Indemnitee&rsquo;s
                                            action is based on the records or books of account of the Enterprise, including financial
                                            statements, or on information supplied to Indemnitee by the directors, managers, managing
                                            members or officers of the Enterprise in the course of their duties, or on the advice of
                                            legal counsel for the Enterprise, its Board, any committee of the Board or any director,
                                            trustee, general partner, manager or managing member, or on information or records given
                                            or reports made to the Enterprise, its Board, any committee of the Board or any director,
                                            trustee, general partner, manager or managing member, by an independent certified public
                                            accountant or by an appraiser or other expert selected by the Enterprise, its Board, any
                                            committee of the Board or any director, trustee, general partner, manager or managing member.
                                            The provisions of this Section&nbsp;13(d)&nbsp;shall not be deemed to be exclusive or to
                                            limit in any way the other circumstances in which Indemnitee may be deemed or found to have
                                            met the applicable standard of conduct set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The knowledge and/or actions, or failure
                                            to act, of any other director, officer, trustee, partner, manager, managing member, fiduciary,
                                            agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining
                                            the right to indemnification under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>14.</B></TD><TD STYLE="text-align: justify"><B>REMEDIES OF INDEMNITEE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">In the event that (i)&nbsp;a determination
                                            is made pursuant to Section&nbsp;12 of this Agreement that Indemnitee is not entitled to
                                            indemnification under this Agreement, (ii)&nbsp;advancement of Expenses, to the fullest extent
                                            permitted by applicable law, is not timely made pursuant to Section&nbsp;10 of this Agreement,
                                            (iii)&nbsp;no determination of entitlement to indemnification shall have been made pursuant
                                            to Section&nbsp;12(a)&nbsp;of this Agreement within thirty (30) days after receipt by the
                                            Corporation of the request for indemnification, (iv)&nbsp;payment of indemnification is not
                                            made pursuant to Sections&nbsp;5, 6, 7 or the last sentence of Section&nbsp;12(a)&nbsp;of
                                            this Agreement within ten (10)&nbsp;days after receipt by the Corporation of a written request
                                            therefor, (v)&nbsp;a contribution payment is not made in a timely manner pursuant to Section&nbsp;8
                                            of this Agreement, or (vi)&nbsp;payment of indemnification pursuant to Section&nbsp;3 or
                                            4 of this Agreement is not made within ten (10)&nbsp;days after a determination has been
                                            made that Indemnitee is entitled to indemnification,&nbsp;Indemnitee shall be entitled to
                                            an adjudication by the Delaware Court to such indemnification, contribution or advancement
                                            rights. Alternatively,&nbsp;Indemnitee, at his or her option, may seek an award in arbitration
                                            to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules&nbsp;and
                                            Mediation Procedures of the American Arbitration Association. Except as set forth herein,
                                            the Commercial Arbitration Rules&nbsp;and Mediation Procedures of the American Arbitration
                                            Association shall apply to any such arbitration. The Corporation shall not oppose Indemnitee&rsquo;s
                                            right to seek any such adjudication or award in arbitration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">In the event that a determination shall
                                            have been made pursuant to Section&nbsp;12(a)&nbsp;of this Agreement that Indemnitee is not
                                            entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to
                                            this Section&nbsp;14 shall be conducted in all respects as a de novo trial, or arbitration,
                                            on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">In any judicial proceeding or arbitration
                                            commenced pursuant to this Section&nbsp;14,&nbsp;Indemnitee shall be presumed to be entitled
                                            to be indemnified, held harmless, exonerated to receive advancement of Expenses under this
                                            Agreement and the Corporation shall have the burden of proving Indemnitee is not entitled
                                            to be indemnified, held harmless, exonerated and to receive advancement of Expenses, as the
                                            case may be, and the Corporation may not refer to or introduce into evidence any determination
                                            pursuant to Section&nbsp;12(a)&nbsp;of this Agreement adverse to Indemnitee for any purpose.
                                            If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section&nbsp;14,&nbsp;Indemnitee
                                            shall not be required to reimburse the Corporation for any advances pursuant to Section&nbsp;10
                                            until a final determination is made with respect to Indemnitee&rsquo;s entitlement to indemnification
                                            (as to which all rights of appeal have been exhausted or lapsed).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If a determination shall have been made
                                            pursuant to Section&nbsp;12(a)&nbsp;of this Agreement that Indemnitee is entitled to indemnification,
                                            the Corporation shall be bound by such determination in any judicial proceeding or arbitration
                                            commenced pursuant to this Section&nbsp;14, absent (i)&nbsp;a misstatement by Indemnitee
                                            of a material fact, or an omission of a material fact necessary to make Indemnitee&rsquo;s
                                            statement not materially misleading, in connection with the request for indemnification,
                                            or (ii)&nbsp;a prohibition of such indemnification under applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Corporation shall be precluded from
                                            asserting in any judicial proceeding or arbitration commenced pursuant to this Section&nbsp;14
                                            that the procedures and presumptions of this Agreement are not valid, binding and enforceable
                                            and shall stipulate in any such court or before any such arbitrator that the Corporation
                                            is bound by all the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Corporation shall indemnify Indemnitee
                                            to the fullest extent permitted by law against all Expenses and, if requested by Indemnitee,
                                            shall (within ten (10)&nbsp;days after the Corporation&rsquo;s receipt of such written request)
                                            pay to Indemnitee, to the fullest extent permitted by applicable law, such Expenses which
                                            are incurred by Indemnitee in connection with any judicial proceeding or arbitration brought
                                            by Indemnitee: (i)&nbsp;to enforce his or her rights under, or to recover damages for breach
                                            of, this Agreement or any other indemnification, advancement or contribution agreement or
                                            provision of the Bylaws now or hereafter in effect; or (ii)&nbsp;for recovery or advances
                                            under any insurance policy maintained by any person for the benefit of Indemnitee, regardless
                                            of the outcome and whether Indemnitee ultimately is determined to be entitled to such indemnification
                                            right, advancement, contribution or insurance recovery, as the case may be (unless such judicial
                                            proceeding or arbitration was not brought by Indemnitee in good faith).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify">Interest shall be paid by the Corporation
                                            to Indemnitee at the legal rate under Delaware law for amounts which the Corporation indemnifies
                                            or advances, or is obliged to indemnify or advance for the period commencing with the date
                                            on which Indemnitee requests indemnification or advancement of any Expenses and ending with
                                            the date on which such payment is made to Indemnitee by the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>15.</B></TD><TD STYLE="text-align: justify"><B>SECURITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, but subject to Section&nbsp;27, to the extent requested by Indemnitee and approved by the Board, the Corporation
may at any time and from time to time provide security to Indemnitee for the Corporation&rsquo;s obligations hereunder through an irrevocable
bank line of credit, funded trust or other collateral. Any such security, once provided to Indemnitee, may not be revoked or released
without the prior written consent of Indemnitee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>16.</B></TD><TD STYLE="text-align: justify"><B>NON-EXCLUSIVITY; SURVIVAL OF RIGHTS;
                                            INSURANCE; SUBROGATION; PRIORITY OF OBLIGATIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The rights of Indemnitee as provided by
                                            this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may
                                            at any time be entitled under applicable law, the Bylaws, any agreement, a vote of stockholders
                                            or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement
                                            or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement
                                            in respect of any Proceeding (regardless of when such Proceeding is first threatened, commenced
                                            or completed) or claim, issue or matter therein arising out of, or related to, any action
                                            taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment,
                                            alteration or repeal. To the extent that a change in applicable law, whether by statute or
                                            judicial decision, permits greater indemnification rights or advancement of Expenses than
                                            would be afforded currently under the Bylaws or this Agreement, then this Agreement (without
                                            any further action by the parties hereto) shall automatically be deemed to be amended to
                                            require that the Corporation indemnify the Indemnitee to the fullest extent permitted by
                                            law. No right or remedy herein conferred is intended to be exclusive of any other right or
                                            remedy, and every other right and remedy shall be cumulative and in addition to every other
                                            right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.
                                            The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent
                                            the concurrent assertion or employment of any other right or remedy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">The Bylaws permit the Corporation to purchase
                                            and maintain insurance or furnish similar protection or make other arrangements, including,
                                            but not limited to, providing a trust fund, letter of credit, or surety bond (&ldquo;<B><I>Indemnification
                                            Arrangements</I></B>&rdquo;) on behalf of Indemnitee against any liability asserted against
                                            him or her or incurred by or on behalf of him or her or in such capacity as a director, officer,
                                            employee or agent of the Corporation, or arising out of his or her status as such, whether
                                            or not the Corporation would have the power to indemnify him or her against such liability
                                            under the provisions of this Agreement and the Bylaws. The purchase, establishment, and maintenance
                                            of any such Indemnification Arrangement shall not in any way limit or affect the rights and
                                            obligations of the Corporation or of Indemnitee under this Agreement except as expressly
                                            provided herein, and the execution and delivery of this Agreement by the Corporation and
                                            Indemnitee shall not in any way limit or affect the rights and obligations of the Corporation
                                            or the other party or parties thereto under any such Indemnification Arrangement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">To the extent that the Corporation maintains
                                            an insurance policy or policies providing liability insurance for directors, officers, trustees,
                                            partners, managers, managing members, fiduciaries, employees, or agents of the Corporation
                                            or of any other Enterprise which such person serves at the request of the Corporation,&nbsp;Indemnitee
                                            shall be covered by such policy or policies in accordance with its or their terms to the
                                            maximum extent of the coverage available for any such director, officer, trustee, partner,
                                            managers, managing member, fiduciary, employee or agent under such policy or policies. If,
                                            at the time the Corporation receives notice from any source of a Proceeding as to which Indemnitee
                                            is a party or a participant (as a witness, deponent or otherwise), the Corporation has director
                                            and officer liability insurance in effect, the Corporation shall give prompt notice of such
                                            Proceeding to the insurers in accordance with the procedures set forth in the respective
                                            policies. The Corporation shall thereafter use commercially reasonable efforts to cause such
                                            insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding
                                            in accordance with the terms of such policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">In the event of any payment under this
                                            Agreement, the Corporation, to the fullest extent permitted by law, shall be subrogated to
                                            the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute
                                            all papers required and take all action necessary to secure such rights, including execution
                                            of such documents as are necessary to enable the Corporation to bring suit to enforce such
                                            rights. No such payment by the Corporation shall be deemed to relieve any insurer of its
                                            obligations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Corporation&rsquo;s obligation to
                                            indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request
                                            of the Corporation as a director, officer, trustee, partner, manager, managing member, fiduciary,
                                            employee or agent of any other Enterprise shall be reduced by any amount Indemnitee has actually
                                            received as indemnification payments or advancement of expenses from such Enterprise. Notwithstanding
                                            any other provision of this Agreement to the contrary, but subject to Section&nbsp;27, (i)&nbsp;Indemnitee
                                            shall have no obligation to reduce, offset, allocate, pursue or apportion any indemnification,
                                            advancement, contribution or insurance coverage among multiple parties possessing such duties
                                            to Indemnitee prior to the Corporation&rsquo;s satisfaction and performance of all its obligations
                                            under this Agreement, and (ii)&nbsp;the Corporation shall perform fully its obligations under
                                            this Agreement without regard to whether Indemnitee holds, may pursue or has pursued any
                                            indemnification, advancement, contribution or insurance coverage rights against any person
                                            or entity other than the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained herein,
                                            the Corporation is the primary indemnitor, and any indemnification or advancement obligation
                                            of any other Person is secondary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>17.</B></TD><TD STYLE="text-align: justify"><B>DURATION OF AGREEMENT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All agreements and obligations
of the Corporation contained herein shall continue during the period Indemnitee serves as a director or officer of the Corporation or
as a director, officer, trustee, partner, manager, managing member, fiduciary, employee or agent of any other corporation, partnership,
joint venture, trust, employee benefit plan or other Enterprise which Indemnitee serves at the request of the Corporation and shall continue
thereafter so long as Indemnitee shall be subject to any possible Proceeding (including any rights of appeal thereto and any Proceeding
commenced by Indemnitee pursuant to Section&nbsp;14 of this Agreement) by reason of his or her Corporate Status, whether or not he or
she is acting in any such capacity at the time any liability or expense is incurred for which indemnification or advancement can be provided
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>18.</B></TD><TD STYLE="text-align: justify"><B>SEVERABILITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any provision or provisions
of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a)&nbsp;the validity, legality and
enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section, paragraph or
sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal
or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by
law; (b)&nbsp;such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give
the maximum effect to the intent of the parties hereto; and (c)&nbsp;to the fullest extent possible, the provisions of this Agreement
(including, without limitation, each portion of any Section, paragraph or sentence of this Agreement containing any such provision held
to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect
to the intent manifested thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>19.</B></TD><TD STYLE="text-align: justify"><B>ENFORCEMENT AND BINDING EFFECT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The Corporation expressly confirms and
                                            agrees that it has entered into this Agreement and assumed the obligations imposed on it
                                            hereby in order to induce Indemnitee to serve as a director, officer or key employee of the
                                            Corporation, and the Corporation acknowledges that Indemnitee is relying upon this Agreement
                                            in serving as a director, officer or key employee of the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Without limiting any of the rights of
                                            Indemnitee under the Bylaws as they may be amended from time to time, this Agreement constitutes
                                            the entire agreement between the parties hereto with respect to the subject matter hereof
                                            and supersedes all prior agreements and understandings, oral, written and implied, between
                                            the parties hereto with respect to the subject matter hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The indemnification and advancement of
                                            expenses rights provided by or granted pursuant to this Agreement shall be binding upon and
                                            be enforceable by the parties hereto and their respective successors and assigns (including
                                            any direct or indirect successor by purchase, merger, consolidation or otherwise to all or
                                            substantially all of the business and/or assets of the Corporation), shall continue as to
                                            an Indemnitee who has ceased to be a director, officer, employee or agent of the Corporation
                                            or a director, officer, trustee, general partner, manager, managing member, fiduciary, employee
                                            or agent of any other Enterprise at the Corporation&rsquo;s request, and shall inure to the
                                            benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators
                                            and other legal representatives.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Corporation shall require and cause
                                            any successor (whether direct or indirect by purchase, merger, consolidation or otherwise)
                                            to all, substantially all or a substantial part, of the business and/or assets of the Corporation,
                                            by written agreement in form and substance satisfactory to Indemnitee, expressly to assume
                                            and agree to perform this Agreement in the same manner and to the same extent that the Corporation
                                            would be required to perform if no such succession had taken place.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Corporation and Indemnitee agree herein
                                            that a monetary remedy for breach of this Agreement, at some later date, may be inadequate,
                                            impracticable and difficult of proof, and further agree that such breach may cause Indemnitee
                                            irreparable harm. Accordingly, the parties hereto agree that Indemnitee may, to the fullest
                                            extent permitted by law, enforce this Agreement by seeking, among other things, injunctive
                                            relief and/or specific performance hereof, without any necessity of showing actual damage
                                            or irreparable harm and that by seeking injunctive relief and/or specific performance,&nbsp;Indemnitee
                                            shall not be precluded from seeking or obtaining any other relief to which he or she may
                                            be entitled. The Corporation and Indemnitee further agree that Indemnitee shall, to the fullest
                                            extent permitted by law, be entitled to such specific performance and injunctive relief,
                                            including temporary restraining orders, preliminary injunctions and permanent injunctions,
                                            without the necessity of posting bonds or other undertaking in connection therewith. The
                                            Corporation acknowledges that in the absence of a waiver, a bond or undertaking may be required
                                            of Indemnitee by a court of competent jurisdiction, and the Corporation hereby waives any
                                            such requirement of such a bond or undertaking to the fullest extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>20.</B></TD><TD STYLE="text-align: justify"><B>MODIFICATION AND WAIVER</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions
of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute
a continuing waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>21.</B></TD><TD STYLE="text-align: justify"><B>NOTICES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All notices, requests, demands
and other communications under this Agreement shall be in writing and shall be deemed to have been duly given (i)&nbsp;if delivered by
hand and receipted for by the party to whom said notice or other communication shall have been directed, or (ii)&nbsp;if mailed by certified
or registered mail with postage prepaid, on the third (3rd) business day after the date on which it is so mailed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">If to Indemnitee, at the address indicated
                                            on the signature page&nbsp;of this Agreement, or such other address as Indemnitee shall provide
                                            in writing to the Corporation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If to the Corporation, to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt; width: 0.5in">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Amicus Therapeutics,&nbsp;Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">3675 Market Street</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Philadelphia, PA 19104</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Attention: Chief Executive Officer</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">With copies, which shall not constitute notice, to:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Amicus Therapeutics,&nbsp;Inc.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">3675 Market Street</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Philadelphia, PA 19104</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Attention: General Counsel</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">and</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Troutman Pepper Hamilton Sanders LLP</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">400 Berwyn Park</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">899 Cassatt Road</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Berwyn, PA 19312</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="background-color: White; font-size: 10pt">Attn: Scott Jones</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">or to any other address as may have been
furnished to Indemnitee in writing by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>22.</B></TD><TD STYLE="text-align: justify"><B>APPLICABLE LAW AND CONSENT TO JURISDICTION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section&nbsp;14(a)&nbsp;of
this Agreement, to the fullest extent permitted by law, the Corporation and Indemnitee hereby irrevocably and unconditionally: (a)&nbsp;agree
that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court and not
in any other state or federal court in the United States of America or any court in any other country; (b)&nbsp;consent to submit to
the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement;
(c)&nbsp;waive any objection to the laying of venue of any such action or proceeding in the Delaware Court; and (d)&nbsp;waive, and agree
not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or
inconvenient forum, or is subject (in whole or in part) to a jury trial. To the fullest extent permitted by law, the parties hereby agree
that the mailing of process and other papers in connection with any such action or proceeding in the manner provided by Section&nbsp;21
or in such other manner as may be permitted by law, shall be valid and sufficient service thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>23.</B></TD><TD STYLE="text-align: justify"><B>IDENTICAL COUNTERPARTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement may be executed
in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute
one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced
to evidence the existence of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>24.</B></TD><TD STYLE="text-align: justify"><B>MISCELLANEOUS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The headings of the paragraphs
of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>25.</B></TD><TD STYLE="text-align: justify"><B>PERIOD OF LIMITATIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No legal action shall be
brought and no cause of action shall be asserted by or in the right of the Corporation against Indemnitee,&nbsp;Indemnitee&rsquo;s spouse,
heirs, executors or personal or legal representatives after the expiration of two years from the date of accrual of such cause of action,
and any claim or cause of action of the Corporation shall be extinguished and deemed released unless asserted by the timely filing of
a legal action within such two-year period; <I>provided, however</I>, that if any shorter period of limitations is otherwise applicable
to any such cause of action such shorter period shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>26.</B></TD><TD STYLE="text-align: justify"><B>ADDITIONAL ACTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If for the validation of
any of the provisions in this Agreement any act, resolution, approval or other procedure is required to the fullest extent permitted
by law, the Corporation undertakes to cause such act, resolution, approval or other procedure to be affected or adopted in a manner that
will enable the Corporation to fulfill its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"><B>27.</B></TD><TD STYLE="text-align: justify"><B>MAINTENANCE OF INSURANCE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Corporation shall use
commercially reasonable efforts to obtain and maintain in effect during the entire period for which the Corporation is obligated to indemnify
the Indemnitee under this Agreement, one or more policies of insurance with reputable insurance companies to provide the officers/directors
of the Corporation with coverage for losses from wrongful acts and omissions and to ensure the Corporation&rsquo;s performance of its
indemnification obligations under this Agreement. The Indemnitee shall be covered by such policy or policies in accordance with its or
their terms to the maximum extent of the coverage available for any such director or officer under such policy or policies. In all such
insurance policies, the Indemnitee shall be named as an insured in such a manner as to provide the Indemnitee with the same rights and
benefits as are accorded to the most favorably insured of the Corporation&rsquo;s directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>SIGNATURE PAGE FOLLOWS</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The parties hereto have caused
this Indemnity Agreement to be signed as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White">AMICUS THERAPEUTICS,&nbsp;INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Signature Page&nbsp;to Indemnity Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; background-color: White"><B>INDEMNITEE</B></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: White; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">Title:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 7%">Address:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;to Indemnity Agreement</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>fold-20221222.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa2N2bOdzZR+yYkxtmBwbcmafyEh+RqfgCQA3QVWYQ0B -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:fold="http://amicustherapeutics.com/20221222" elementFormDefault="qualified" targetNamespace="http://amicustherapeutics.com/20221222">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://amicustherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20221222_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="fold-20221222_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>fold-20221222_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>fold-20221222_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://amicustherapeutics.com/role/Cover" xlink:href="fold-20221222.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://amicustherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140048400100816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 22,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AMICUS THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">921-7600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>tm2233572d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="fold-20221222.xsd" xlink:type="simple"/>
    <context id="From2022-12-22to2022-12-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-12-22to2022-12-22">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-12-22to2022-12-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-12-22to2022-12-22">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-12-22to2022-12-22">2022-12-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-12-22to2022-12-22">AMICUS THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-12-22to2022-12-22">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-12-22to2022-12-22">001-33497</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-12-22to2022-12-22">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-12-22to2022-12-22">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-12-22to2022-12-22">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-12-22to2022-12-22">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-12-22to2022-12-22">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-12-22to2022-12-22">215</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-12-22to2022-12-22">921-7600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-12-22to2022-12-22">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-12-22to2022-12-22">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-12-22to2022-12-22">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-12-22to2022-12-22">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-12-22to2022-12-22">Common Stock Par Value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-12-22to2022-12-22">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-12-22to2022-12-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-12-22to2022-12-22">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !2(G%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  4B)Q5V:'K;>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TUAD=#M1?&D(+B@> N3V=U@TX1DI-VWMZV[740?P&-F_GSS
M#4R#46-(])Q"I,2.\LWHNSYKC%MQ9(X:(..1O,GEE.BGYCXD;WAZI@-$@Q_F
M0*"DW( G-M:P@1E8Q)4HVL:BQD2&0SKC+:[X^)FZ!681J"-//6>HR@I$.T^,
MI[%KX J884S)Y^\"V96X5/_$+AT0Y^28W9H:AJ$<ZB4W[5#!V]/CR[)NX?K,
MID>:?F6G^11I*RZ37^N[^]V#:)54JJA4H6YW2FDI=;UYGUU_^%V%?;!N[_ZQ
M\46P;>#77;1?4$L#!!0    ( !2(G%697)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M5>8&N+Z14A\'9K=:_K-A_"]02P,$%     @ %(B<59^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !2(G%4L4Q;)2@0  '@0   8
M          " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  4B)Q5GZ ;\+$"  #B#   #0              @ &,#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !2(G%67BKL<P    !,"   +
M  "  6@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !2(G%6JQ"(6,P$  "("
M   /              "  5$0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  4B)Q5)!Z;HJT   #X 0  &@              @ &Q$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  4B)Q599!YDAD!  #/ P
M$P              @ &6$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  #@$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2233572d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://amicustherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm2233572d1_8k.htm">tm2233572d1_8k.htm</File>
    <File>fold-20221222.xsd</File>
    <File>fold-20221222_lab.xml</File>
    <File>fold-20221222_pre.xml</File>
    <File>tm2233572d1_ex10-1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm2233572d1_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm2233572d1_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20221222_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20221222_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20221222.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fold",
   "nsuri": "http://amicustherapeutics.com/20221222",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2233572d1_8k.htm",
      "contextRef": "From2022-12-22to2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://amicustherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm2233572d1_8k.htm",
      "contextRef": "From2022-12-22to2022-12-22",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://amicustherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001104659-22-130567-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-130567-xbrl.zip
M4$L#!!0    ( !2(G%4)?N5]0@,  !,,   1    9F]L9"TR,#(R,3(R,BYX
M<V2U5MM2VS 0?6YG^@^J7QG%L5-H"0D,E])A)D )Y?K2460YT2!+1I))Z-=7
MDNTD)"8DH?63O#KG[*ZTNW9K;Y0P\$2DHH*WO:!6]P#A6$24]]O>U27<OSP\
M.?' WNZGC\ \K<\0@F-*6-0$1P+#$QZ+'7"&$M($/P@G$FDA=\ U8IFUB&/*
MB 2'(DD9T<1LY)Z:8+,6;&$ X1*ZUX1'0EYU3\:Z ZU3U?3]X7!8X^()#85\
M4#4LDN4$+S72F1JKU4?UXEF.?DH5'I,WT/[F\.NH2V_[A'_+.JAQCV]0>!;V
MSJ,_]]V-Y[N'D4X.ACV<H/CY^V"C^QCW#R_V&Q?7-W<7]8/<94OA 4D0,)?!
M5=NS^17I#1LU(?M^6*\'_NUIY]+AO!S8'#'*'ZK@P?;VMN]V2^@<<M23K)1N
M^':[AQ09*YM=N@!/N=*(XQ?X2(\)T^!-/]]\ :65T*T<2DMH1&9PBN!:7SSY
M9L/@P^#Q2PG-%.PCE([A,5(])UML.#BL![ 1E!0E]3S<&*NA4#^G1%42\JT*
M6BQ8-&:@A.),Z8'ID91DFF)7L985!F$8FKYC)"%<'PN9')$89<R$]Y@A1F-*
M(@]H)/M$VQ)4*<)D:=VRHA'GPA2^Z;["8FUI2DUE&\.'EBV!IA2,_#+9 +LP
M+?>6%POS#X49(!Z@)M=\:?6,NE.,2$PY=6Z++@L M#V5V63-TE%:_BQX2B)3
M)#KGNVZ=2J(,S^71,8:"6$!>(6'$<,96XTQ"J:04AO*\)B=8=E*7Q,!U8--6
M1]M3U,Y K[ -)(G;GJT/6%[4;Y-:S=1-";'2"SK0G?SL:12.2PDD\9S*W(0P
M(B(E4E-3PE-C( ^=:DO_.>4&6#_* _Z_2)FAWJHI&PIA_S'7CM6?3K)H%7_2
M*\7[;#^U3+I":L#G6G31_,PG?T=@)[6 8M]@R8/6!(/0#)O:2$632%<)8G("
MJP51\M8(XM4I7A6!>IU@ES!?+NMZX1=AH?M*ID^85J4%3K36"6?^^_&.>)S8
M&@&]N.Q(2]\*6>FZU0D7!/46T[VKM4H$BXQK^>PR7+)(IBGEBSN.E6]F]E]@
MN4LI6?F%V-^#=Q1']=_%NH&\7AHM/]<TR[]02P,$%     @ %(B<510CQU[_
M"@  ;(<  !4   !F;VQD+3(P,C(Q,C(R7VQA8BYX;6S-G5]3Z[@9QN\[T^^@
M36_:F1-"0KLSL(?=X>3 #K,LL(1SMNU.9T>Q1?#@2*SL0/+M*]F68TMZ;4.G
MDKB 8#VO_,CZ19+_2/[XPW:=HA?"LX31T]'TX'"$"(U8G-#5Z>C+8GRVF%]>
MCE"68QKCE%%R.J)L],/W?_X3$C\?OQF/T45"TO@$?6;1^)(^L._0-5Z3$_0C
MH83CG/'OT%><;N06=I&DA*,Y6S^G)"<BH=SQ"?K'P?3;"(W' _+]2FC,^)>[
MRSK?QSQ_SDXFD]?7UP/*7O KXT_90<36PS)<Y#C?9'5NA]O#ZJ<,_Y@F].E$
M_EKBC"!QO&AVLLV2TY'<;[7;UZ,#QE>3V>'A=/+/GZ\6T2-9XW%"Y7&+R$A%
MR5QL<=/CX^-)D:JDAG*[Y*G:Q]%$V:ES%JE)A[[A)$M.LL+>%8MP7E1[[VX0
MJ)#_C95L+#>-I[/QT?1@F\4C=?"+(\A92N[( RJ*>9+OG@5*62))&%7;'CEY
ML)M).9_(^ DE*YR36.[H6.YH^JW<T5^JS5=X2=(1DDK!!UBNXU9>5=#$M=E;
MPA,6G]/WN=:C/=D7WQV>_P\%:,8[+\(]RW'Z+O/-2.>VK\G[CO@^SOV1%NT\
M>=^1;D3^7VSGIN4W'U[[<4WEQBOQJ661;'/1@9%8F919=+3 Q1Z*CJ'*N\Z=
M1:U\4]F:,VZ67?:,19X9B0Y6[&42DT3D/9O^\7?Y<5Q^+(HN_OU]SL1HX&R9
MY1Q'N<JM*,KIR)(^T6U)Y1E7WC"/>@I8*281$]W3<SY.RT-9AC]PMK;NMBHY
MLR3^GB[K^/+0B%T 1ELR3C*VX1%Y4\TTW4)'J7*T3H5"#JL('7]9C+XO-.@W
MI?K/Q\D^%T>5+89"FS6A^;W(U5**=K*KJK:94C7=3 NBHBV&]'I6$B0U'BKY
M3.P\E@8N4KRR%$%+=U7-5ENJGEN)052TS9%>T[4&29'/JOY,LH@GSW)XWU66
MELQYQ5M,&O7?T(2%@6D,IJ&A]=C(WY%5(KL::4.>\Q*YL:-) _2NNX%.VWJ_
M8!4' <X0AV#/T0Q"=91'ELXHW>#TCCPSWH506^::')M)'9BF)BA.+,9 /$HM
M*L4>J?AE(\[F"4]WO6 82M=L %9U/#194(38O8&0U'+_G-QS3+-$-F:]H)A2
MYZ<A@%GCE$33!<4*8 X^5:GU_FE9/)(TE?<,,.UO6&QBU\3 AG5F3&50U(#V
M0&Z*"%2%A(7.^8L<M8NAT\ "-_0^ 3)L=S%4BX/%2'<XD*0B#,DXCS0U;EGT
M<&0H71,$6-79T61!46/W!O)2RE&A#P.4<QH/PJ36^8%$LVE'I!(%"$C;61\>
M0NT;CHLDBW!:^KD0V[*.(EJTKB$![>J@&,*@8('<@<"4 8J;(L0[-/\BF ]#
MIJ'T XQAU8Y++0L0%MU;'RI2[PV4^8;SEG.X]X&ESF[F]IBM[^L"NB!@Z3%G
MW.TMY2U8//9&YS1/\IU\'N]ZLUX2;BF@*7'%!V1.<:&G!\$#8$KGH)0AJ4.E
MT%OMJ[L*-)</0H)%TF5N*;";;)/0U@1$@]480,1>6SR7ZHV*N6BE.$XO:4RV
M/Y$=6#9#YY8+P&8;#$T4$!EV9P :E1@5:B3DWN"XY<D:\]TBB7JZ#5/H%@_(
M:)L/7140(( U@)!*C1:7<]^]RCW>7L8"V.0A*9\O[R$%U+L%IL=VFQM '! ^
MW0X!BD00:D?YANF21HP_L\;C$G.V$8WA;LYB>,32$^46K$%%:./5&1(09$-\
M JBU0C^4S[0@)N<&%1D@F8,WZL[B6!RLK/ISE5 R!8^!5>N6L Z[;:XLPH!H
M@MT!#%7*#^H#DC'HAH8$SNP-Q9WY!V<V%)Q9T.#,W@/._2L+")RC-Q3WR#\X
M1T/!.0H:G*-W@2,JWWN;,Q<?;_@]>[4]\ TJO6!C6K5"LY>%AXSAK0\8&2#'
M-S+$-RK%8.N&WW+VDM ('D9#<B_0 *:MY&C:\/"Q&^QCJ!XDJSC?(%6#]=XO
MBY+Y:6W:)NU-3:D)#Y2VL=Y&IE3[QN*693E._YT\=YZDV\5>$+$:MH+24H:'
MB\U>'S1E#!)!ODZZ*VSE#1#K=#4MW=V48XNM_93C1F(0(-@<F5..RZLKI<A'
M54M6.<% R]!.=E;1%E-U/3?2PJAFTY!1R\7W6VA\?:'ERC+I[2.C\,,%IL15
M;4/F5(WKZ4'4.F!*K_E"A@J=QROW<H6+S-Z4-]*<]?2ZG;IC5PE!U+#NQNBV
M5;J'&OV5)[G8^YRMUQM:W1FR/8,(Z%S5=*=-5>M641 $=#G3::BTJ"WV@,:"
MI4F4Y E=_2Q.3GF";26SB5Q! 1M41)B*('  ;>DL[(5(*3V <,N)A)&(RB@F
M',I%COC-PX.U]^\2NP*CW[ "!%8& 4JO/1T8$3".&A&H#$%%C']T+K-L0_B;
M +*$>,((- _ 9.A#1 HRV0M6&>B;KP6)-J*_W$UGR_LD3VTGGJ;$6?\$F*M[
M)RT]"#X 4SH/11IB#V@Z^^OR;TA%>4#@FMUS+!>U7>S62Y8"*V%95:Y Z+"H
M6+!(@L !]J43<<U0)46EUM=*62W#EB)IZ:X@L-I2U=]*#*+B;8Z,1J!5WQZ;
M__-M]"B,$6"R@UWFNANPF=2[@J8F" PZC!DG*Y44*:VOR0[[+FS5/RA8>1L4
MK'H&!:L0!P6KH8."E==!@=IUN4R):*-NEFFRPL"BB9UJUV!T6-89L4B#P@7V
M![8==0C:Q_A8;;-8=DV^2H"O"P\7XH.EI(#.V7J;73;K!3=MHB XZ7)F++E9
M+H37$".I]L'&)DYR$I>&+A**:93@M%ZZT7;UO#_$&3$#S=?P].C#X&B820.I
M,DRML5@'[I?A]''9O7R(XU>2IC]1]DH7!&>,DKB\WF*[N]2M=_O438_M]H,W
M@#@(I(8X!!Z_D4'C)QF%5%AUM<P;35]9NJ$YYL4<=FYKH0"=6WH FVUJ-%%
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M"GC=GA+#!M=+<P84<%'7<1$"PW%Q7R&2XN!M0AZ5-J4J ZV./8)>F&/D )Z
MZ)6$I>^*GQT4IE^XO&"$H8! #?&WTX6N.%?@T(&-(H1I0W?8.&QY*\J13ADV
M=(HI2H@WQ:P#XA$^3D6+R@QA<KR3=B3UZ0$\6' S#0/&X@E;AX(0>G,I^KX'
M#D-<O@J=<P_1YL+_=,.Z(8Y9<'G*@M)[5-2^O"P5O,HBH!+.QA<J4"J\1-+
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M]Z\[\>Y*(G:L)F"Q@!XK\1)P8D]PF#LI0DE(K_A_?'_-5)SI>Z3$^-0TC]A
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MG(W.8;L*\4#GW4W#2VUI7#1D5-;$"5UHA ?VJTX%7 !3ISQ<#+\%*U7 (S2
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M.)KEF:HP,21L64UKB&Z:I(=7:HD-!HBYEQBZ>]IW3+)X#'*%OPJ,5,SF!8(
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M,#(R,3(R,BYX<V102P$"% ,4    "  4B)Q5%"/'7O\*  !LAP  %0
M        @ %Q P  9F]L9"TR,#(R,3(R,E]L86(N>&UL4$L! A0#%     @
M%(B<5<XQG-Q<!P  U5@  !4              ( !HPX  &9O;&0M,C R,C$R
M,C)?<')E+GAM;%!+ 0(4 Q0    ( !2(G%6NUW^+JAH  .&%   2
M      "  3(6  !T;3(R,S,U-S)D,5\X:RYH=&U02P$"% ,4    "  4B)Q5
MV9]^8_I0  "<10( %@              @ $,,0  =&TR,C,S-3<R9#%?97@Q
=,"TQ+FAT;5!+!08     !0 % $D!   Z@@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
